Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 5Recruiting 2Not yet recruiting 2Completed 2

Sponsor Class

OTHER 49OTHER_GOV 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

tislelizumab 12Capecitabine 8apatinib 5Surgical Procedures, Operative 5Carboplatin 5Oxaliplatin 4Drug Therapy 4Cisplatin 4Radiation 3Paclitaxel 3Immunotherapy 3Bevacizumab 3toripalimab 2anlotinib 2Standard of Care 2Radiotherapy 2Methods 2Melphalan 2Low-Level Light Therapy 2Letrozole 2Interleukin-2 2Injections 2Cryotherapy 2130-nm albumin-bound paclitaxel 2zanubrutinib 1trastuzumab deruxtecan 1sintilimab 1pyrotinib 1pertuzumab 1obinutuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER_GOV × anlotinib × Clear all
NCT07470840 2026-03-24

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Fujian Cancer Hospital

Phase 2 Not yet recruiting
27 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07363512 2026-01-23

Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus

Henan Cancer Hospital

Phase 2 Not yet recruiting
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡